Momentum Stock in Focus - Rockwell Medical, Inc. (NASDAQ:RMTI) - Enterprise Leader Print

According to Zacks, Rockwell Medical, Inc. (NASDAQ:RMTI) has been given a high momentum style score. The score calculation is based on a number of factors indicating that the stock might be at a favorable level to enter a position based on the recent upward or downward movement of the equity. Traders buying or selling on momentum look at stock price trends and believe that the stock will continue to move in the same direction. This strategy is typically only used by experienced traders and is based solely on short-term price movements instead of company fundamentals or research.

Potential investors in the stock might look to analyst research, past earnings history and future prospects in addition to the momentum of the stock. Zacks Research currently has a stock rating of 2.55 on the equity. This is the consensus mean from the analysts who have issued ratings on the stock within the past year. This number is calculated using a simple 1-5 scale where 1 represents a Strong Buy rating and 5 represents a Strong Sell rating. In other words, the lower the score, the better from an analyst perspective. Sell-Side Perspective Brokerage firm research analysts covering Rockwell Medical, Inc. (NASDAQ:RMTI), on a consensus basis, are projecting that the stock moves to $15. This is the one year price target given by sell-side analysts covering the equity. The firm that sees the most upside has their target set at $26. The least optimistic analyst has their target at $4. Analysts are predicting that Rockwell Medical, Inc. will report earnings of $0.09 per share when the firm is scheduled to release their quarterly numbers on 2015-11-09. For the most recent period ending on 2015-06-30, the company reported earnings per share of $-0.05. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.